|
An interventional study of the impact of digital patient monitoring (DPM) on health outcomes, healthcare resource utilization, and feasibility of a combination with at-home treatment (tx) for delivery of systemic anticancer tx in clinical practice. |
|
|
Consulting or Advisory Role - AstraZeneca; BMS; Boehringer Ingelheim; MSD Oncology; Novartis; Pierre Fabre; Roche; Takeda |
Research Funding - AstraZeneca (Inst); Roche (Inst) |
|
|
Leadership - Lung Cancer Europe |
Honoraria - AstraZeneca; Roche |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst); Thermo Fisher Scientific (Inst) |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Honoraria - Bristol-Myers Squibb (Inst); Novartis; Roche (Inst); Vifor Pharma (Inst) |
Consulting or Advisory Role - Roche (Inst) |
Research Funding - Bristol-Myers Squibb (Inst); Kaiku Health (Inst); Roche (Inst) |
Expert Testimony - Bristol-Myers Squibb (Inst) |
Travel, Accommodations, Expenses - Vifor Pharma (Inst) |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Celgene; Clovis Oncology; Eisai; GlaxoSmithKline; Janssen; Lilly; Merck; MSD; Novartis; Roche |
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Celgene; Clovis Oncology; Eisai; GlaxoSmithKline; Janssen; Lilly; Merck; MSD; Novartis; Roche |
|
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Celgene; Clovis Oncology; Eisai; GlaxoSmithKline; Janssen; Lilly; Merck; MSD; Novartis; Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
|